Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

2.785 -0.105 (-3.63%)
Streaming Delayed Price Updated: 11:19 AM EDT, May 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Taysha Gene Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Analyzing Taysha Gene Therapies's Short Interest
Taysha Gene Therapies's (NASDAQ:TSHA) short percent of float has fallen 5.27% since its last report. The company recently reported that it has 889 thousand shares sold short, which is 4.31% of all... 
Via Benzinga
Why Is Xerox (XRX) Stock Down 20% Today?
Xerox (XRX) stock is heading lower on Tuesday thanks to the release of its earnings report for the third quarter of 2022. 
Via InvestorPlace
Taysha Gene Therapies (NASDAQ: TSHA) Receives $50 Million Strategic Investment From Astellas Pharma to Develop AAV-Based Gene Therapeutics
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a biotechnology company that is focused on developing gene therapies to treat monogenic 
Via Spotlight Growth
What Is Going on With Taysha Gene (TSHA) Stock Today?
Taysha and its new partner Astellas are both speculating that Adeno Associated Viruses can create treatments for genetic diseases. 
Via InvestorPlace
Astellas Pharma Invests $50M To Support Taysha's Gene Therapy Programs
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
Expert Ratings for Taysha Gene Therapies
Within the last quarter, Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings: 
Via Benzinga
Taysha Gene Therapies: Q1 Earnings Insights
Taysha Gene Therapies (NASDAQ:TSHA) reported its Q1 earnings results on Monday, May 16, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For May 16, 2022
Companies Reporting Before The Bell • AcelRx Pharmaceuticals (NASDAQ:ACRX) is estimated to report quarterly loss at $0.06 per share on revenue of $550.00 thousand. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Taysha Gene Therapies (NASDAQ:TSHA) stock increased by 36.4% to $2.06 during Tuesday's pre-market session. The market value of their outstanding shares is at $84.6 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with an overview of the biggest pre-market stock movers on Tuesday and the latest news this morning! 
Via InvestorPlace
Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose 43% to $2.16 in pre-market trading. Astellas Pharma Inc. announced plans to invest a total of $50 million to acquire 15% of Taysha Gene... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low. 
Via Benzinga
Taysha Gene Therapies Lays Off 35% Of staff, Narrows R&D Focus
Taysha Gene Therapies Inc (NASDAQ: TSHA) is the latest company to slim down by  
Via Benzinga
What 4 Analyst Ratings Have To Say About Taysha Gene Therapies
  Taysha Gene Therapies (NASDAQ:TSHA) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 215 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday, 198 companies reached new 52-week lows. 
Via Benzinga
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Gainers Digital Media Solutions, Inc. (NYSE: DMS) jumped 78.8% to close at $2.11. Digital Media Solutions recently reported worse-than-expected Q2 EPS and sales results. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
On Tuesday, 540 companies set new 52-week lows. 
Via Benzinga
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday, 213 companies hit new 52-week lows. 
Via Benzinga
What 6 Analyst Ratings Have To Say About Taysha Gene Therapies
Analysts have provided the following ratings for Taysha Gene Therapies (NASDAQ:TSHA) within the last quarter: 
Via Benzinga
10 Biggest Price Target Changes For Friday
Wells Fargo lowered the price target on General Motors Company (NYSE: GM) from $83 to $72. GM shares rose 0.8% to $44.10 in pre-market trading. 
Via Benzinga
Recap: Taysha Gene Therapies Q4 Earnings
  Taysha Gene Therapies (NASDAQ:TSHA) reported its Q4 earnings results on Thursday, March 31, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via Business Wire
Taysha Gene Therapies's Earnings Outlook
Taysha Gene Therapies (NASDAQ:TSHA) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Earnings Scheduled For March 31, 2022
Companies Reporting Before The Bell • Trevena (NASDAQ:TRVN) is likely to report earnings for its fourth quarter. 
Via Benzinga
The Daily Biotech Pulse: Roche's Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome
From Taysha Gene Therapies, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.